RecruitingPhase 1NCT07234942

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)

Studying Early-onset autosomal dominant Alzheimer disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Hoffmann-La Roche
Principal Investigator
Clinical Trials
Hoffmann-La Roche
Intervention
RO7812653(drug)
Enrollment
50 target
Eligibility
50-75 years · All sexes
Timeline
20262030

Study locations (6)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07234942 on ClinicalTrials.gov

Other trials for Early-onset autosomal dominant Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for Early-onset autosomal dominant Alzheimer disease

← Back to all trials